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Statistical and Clinical Significance in ORBITA Placebo-Controlled PCI Trial 
Mohamad Fahed Barakat,1,2 Panagiotis Simitsis 2  
1Kings College London BHF Centre of Research Excellence, Cardiovascular 
Division, London, UK. 
2 Kings College Hospital, London, UK. 
 
We applaud ORBITA as a well-executed first placebo-controlled trial of the 
incremental impact of PCI on exercise time (ET) in stable angina.1 However, given 
the study’s importance, we were surprised by the statistics. Using an unpaired t-test, 
the authors compared change in ET between treatment groups and found “no 
difference” (16.6 seconds,95%CI:-8.9 to 42.0,p=0.20). However, in parallel 
randomized trials, mixed effects models such as an analysis of covariance 
(ANCOVA) are indicated as they carry more precision, correct for baseline 
imbalances that predispose to regression to the mean, and confer greater statistical 
power to detect small but clinically meaningful differences.2,3 According to their 
exercise protocol,4 a 16.6 second ET increment (on top of optimal drugs) brought 
PCI patients up into the ≥7.9 metabolic equivalent category linked to a 29% relative 
reduction in mortality.5 Thus, the treatment effect might be clinically and statistically 
significant. At baseline, ET was unbalanced and higher in PCI patients (528.0±178.7 
vs 490.0±195.0), implying that the treatment effect could be underestimated due to 
regression to the mean.2,3 More importantly, an unpaired t-test shows that the end of 
study ET is statistically higher with PCI (556.3±178.7 vs 501.8±190.9,p=0.04) albeit 
without adjustment. Given that the baseline ET imbalance biases the results against 
PCI with change-over-time statistics, could the authors give us the ANCOVA p-value 
after adjustment for baseline ET. Because hesitant use of PCI could conceivably 
harm patients, it is imperative that the ORBITA results remain publically valid even 
after more appropriate ANCOVA testing.  
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